Drug Trial Radar · NCT06508931
Safety and Efficacy Study of Zamtocabtagene Autoleucel (MB-CART2019.1) in Pediatric Patients With R/R B-Cell Neoplasms
Last checked: Nov 20, 2026Latest source record: May 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
31
Planned (sponsor's estimate)
Start
Aug 4, 2025
Primary completion
Dec 31, 2029
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Miltenyi Biomedicine GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- PPD, Part of Thermo Fisher Scientific
- First posted
- Jul 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 6 months, up to 17 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric and adolescent subjects (aged between 6 months and \<18 years, ≥6 kg body weight \[BW\]) with mature B-cell neoplasms and aggressive lymphomas that relapsed after or are refractory to one or more prior therapies, including subjects with primary refractory disease.
Conditions
- B-Cell Neoplasm
Interventions
zamtocabtagene autoleucel (MB-CART2019.1)Drug
Tandem CD20-CD19-directed non-cryopreserved CAR-T cell therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- BORR, Best Overall Response RateTime frame: From infusion until week 78
- Type, frequency, and severity of adverse events (AEs), serious adverse events (SAEs), and adverse events of special interest (AESI) [Safety and toxicity of the study product]Time frame: From infusion until week 78
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
Institut Gustave Roussy
Villejuif, France · Recruiting
Hôpital Robert Debré
Paris, Boulevard Sérurier 48, France · Active not recruiting
Universitaetsklinikum Muenster (UKM) - Klinik fuer Kinder- und Jugendmedizin - Paediatrische Haematologie und Onkologie
Münster, Albert-Schweitzer-Campus 1, Gebaeude A1, Germany · Active not recruiting
IRCCS Ospedale Pediatrico Bambino Gesù
Rome, Piazza Sant Onofrio 4, Italy · Recruiting
Prinses Maxima Centrum
Utrecht, Heidelberglaan 25, Netherlands · Active not recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.